Press releases
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
More ▼
Key statistics
On Friday, Stoke Therapeutics Inc (0GT:STU) closed at 11.50, -28.57% below its 52-week high of 16.10, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.50 |
Low | 11.50 |
Bid | 11.90 |
Offer | 12.30 |
Previous close | 11.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.12m |
Free float | 49.74m |
P/E (TTM) | -- |
Market cap | 683.81m USD |
EPS (TTM) | -2.42 USD |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼